Digestive System Diseases  >>  linsitinib (ASP7487)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linsitinib (ASP7487) / Sling Therap
NCT01334710: A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Terminated
2
3
US
Sorafenib and OSI-906, Nexavar
Emory University, OSI Pharmaceuticals
Liver Cancer
08/11
12/11
NCT01101906 / 2010-018739-17: A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Terminated
2
23
US, Europe, RoW
OSI-906, Placebo
Astellas Pharma Inc
Advanced Hepatocellular Carcinoma (HCC)
11/11
12/11
NCT01560260: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
20
US
Laboratory Biomarker Analysis, Linsitinib, IGF-1R inhibitor OSI-906, OSI-906, OSI-906AA, Pharmacological Study
National Cancer Institute (NCI)
Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
10/15
10/15
NCT01600807: OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Withdrawn
1/2
0
US
Gemcitabine, Erlotinib, OSI-906, Gemzaar, Tarceva, Gemcitabine, Erlotinib
Dana-Farber Cancer Institute
Pancreatic Cancer, Metastatic
 
 

Download Options